In terms of adoptive cell therapy, the translational implications of decitabine or guadecitabine synergism with infusion of donor-derived NK cells, CD123/NKG2D CAR-T or WT1 TCR-T cells targeting AML and MDS cells represent fertile areas for future investigations. This evidence concerns the gene IL3RA and myelodysplastic syndrome.